How JAK Inhibitors Have Shaped the Landscape of MF

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how JAK inhibitors have reduced spleen size (splenomegaly) and constitutional symptoms like fatigue and fever in patients with myelofibrosis but that there is still room for improvement in treating other aspects of the disease like anemia and bone marrow fibrosis. They also share insights about the potential for combination therapies that target multiple pathways.

Related Content:

Year in Review: Updates in Treating MyelofibrosisMyeloproliferative NeoplasmsHematologic Oncology

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management